Showing 2690 results
-
Statement /
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Statement /
-
Media Library / -
Media Library / -
Media Library / -
Statement /
-
Story /Novartis has been at the forefront of advances in how blood cancers and serious blood disorders are treated, helping patients live their best lives.
-
Statement /
-
Statement /
-
Story /Hear from Director of Patient Services at AAMDSIF on how she supports patients with PNH, a blood disorder that significantly impacts quality of life.